← All trials
NCT04641143
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 22, 2020
- Primary completion
- Mar 17, 2023
- Completion date
- Mar 17, 2023
- First posted
- Nov 23, 2020
- Last posted
- Dec 29, 2020
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Biohaven Pharmaceuticals Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.